Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
NTLA on Nasdaq
Shares outstanding
107,809,066
Price per share
$8.99
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
104,170,311
Total reported value
$1,798,838,423
% of total 13F portfolios
0%
Share change
+5,039,963
Value change
+$103,534,413
Number of holders
277
Price from insider filings
$8.99
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 11% $205,844,204 11,919,178 ARK Investment Management LLC 30 Sep 2025
VANGUARD GROUP INC 10% $75,507,552 10,189,953 The Vanguard Group 31 Dec 2024
BlackRock, Inc. 8.2% $62,636,834 8,453,014 BlackRock, Inc. 31 Mar 2025
Contrarius Investment Management Ltd 5.5% $101,719,195 5,889,936 Contrarius Investment Management Ltd 30 Sep 2025
GOLDMAN SACHS GROUP INC 5.1% $94,954,991 5,498,262 THE GOLDMAN SACHS GROUP, INC. 30 Sep 2025
STATE STREET CORP 4.4% $33,421,034 4,510,261 STATE STREET CORPORATION 31 Mar 2025

As of 30 Sep 2025, 277 institutional investors reported holding 104,170,311 shares of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA). This represents 97% of the company’s total 107,809,066 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARK Investment Management LLC 11% 11,919,178 -8.4% 1.2% $205,844,200
VANGUARD GROUP INC 10% 11,044,820 +1.8% 0% $190,744,040
BlackRock, Inc. 8.6% 9,275,817 -7.5% 0% $160,193,355
MORGAN STANLEY 5.6% 6,022,576 +46% 0.01% $104,009,912
Contrarius Group Holdings Ltd 5.5% 5,889,936 +279% 4.6% $101,719,195
STATE STREET CORP 4.6% 4,970,869 +23% 0% $85,846,908
GOLDMAN SACHS GROUP INC 4% 4,278,677 +109% 0.01% $73,892,752
REGENERON PHARMACEUTICALS, INC. 3.4% 3,702,995 0% 9.1% $63,950,724
BAKER BROS. ADVISORS LP 2.5% 2,746,674 +2.7% 0.34% $47,435,060
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,588,854 -0.67% 0% $44,714,752
TWO SIGMA INVESTMENTS, LP 2.3% 2,449,607 +7.6% 0.06% $42,304,713
Sumitomo Mitsui Trust Group, Inc. 2.2% 2,354,856 -12% 0.02% $40,668,363
Amova Asset Management Americas, Inc. 2.2% 2,354,856 -12% 0.39% $40,621,266
D. E. Shaw & Co., Inc. 2.1% 2,228,400 +170% 0.03% $38,484,468
TWO SIGMA ADVISERS, LP 2% 2,163,417 +3.4% 0.07% $37,362,212
FMR LLC 1.7% 1,852,292 +22% 0% $31,989,079
DIMENSIONAL FUND ADVISORS LP 1.6% 1,757,294 -5.8% 0.01% $30,346,421
VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.5% 1,610,205 +3.7% 0.09% $27,808,240
JUPITER ASSET MANAGEMENT LTD 1.3% 1,361,849 0.2% $23,519,132
UBS Group AG 1% 1,108,186 +26% 0% $19,138,372
NORTHERN TRUST CORP 0.84% 906,292 -0.3% 0% $15,651,663
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.83% 890,361 +17% 0.02% $15,376,534
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.81% 873,188 +1.9% 0% $15,079,957
STIFEL FINANCIAL CORP 0.72% 778,516 -0.83% 0.01% $13,444,998
ARMISTICE CAPITAL, LLC 0.62% 672,000 +3.4% 0.36% $11,605,440

Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 206,071 $1,860,679 -$185,690 $8.99 12
2025 Q3 104,170,311 $1,798,838,423 +$103,534,413 $17.27 277
2025 Q2 99,520,897 $933,579,792 -$6,825,663 $9.38 277
2025 Q1 101,251,781 $719,977,468 +$1,659,576 $7.11 288
2024 Q4 99,184,644 $1,156,445,705 -$48,845,672 $11.66 287
2024 Q3 93,142,351 $1,913,945,494 +$51,155,794 $20.55 277
2024 Q2 90,092,575 $2,016,358,949 -$18,718,668 $22.38 288
2024 Q1 90,368,572 $2,485,713,813 +$142,265,755 $27.51 279
2023 Q4 286,675 $8,769,009 +$383,052 $30.49 5
2023 Q3 78,946,049 $2,496,395,327 +$57,843,450 $31.62 274
2023 Q2 77,056,920 $3,140,539,158 -$39,843,798 $40.78 280
2023 Q1 78,270,994 $2,911,896,224 +$28,176,289 $37.27 280
2022 Q4 77,545,659 $2,705,027,372 +$329,114,536 $34.89 288
2022 Q3 67,861,717 $3,795,800,579 -$10,090,936 $55.96 301
2022 Q2 67,541,488 $3,439,548,938 +$101,970,669 $51.76 279
2022 Q1 64,697,930 $4,683,526,066 -$33,755,256 $72.67 335
2021 Q4 63,864,785 $7,555,674,072 +$199,963,764 $118.24 356
2021 Q3 61,777,039 $8,288,248,318 +$33,759,132 $134.15 355
2021 Q2 61,939,322 $10,038,784,348 +$30,007,362 $161.91 330
2021 Q1 62,800,280 $5,039,887,130 +$266,827,924 $80.25 253
2020 Q4 61,444,884 $3,342,736,371 +$176,602,315 $54.40 232
2020 Q3 56,360,007 $1,122,649,782 +$49,243,199 $19.88 158
2020 Q2 53,924,146 $1,127,157,668 +$160,934,073 $21.02 158
2020 Q1 46,446,764 $568,083,328 +$9,025,160 $12.23 133
2019 Q4 45,615,433 $669,177,528 +$24,351,456 $14.67 136
2019 Q3 44,102,533 $588,744,766 +$69,152,709 $13.35 130
2019 Q2 38,747,662 $634,232,544 +$80,381,973 $16.37 140
2019 Q1 33,462,330 $569,906,589 +$44,700,415 $17.08 141
2018 Q4 31,485,149 $429,741,276 +$12,297,790 $13.65 134
2018 Q3 29,098,874 $832,839,044 +$9,975,781 $28.62 149
2018 Q2 28,758,802 $786,734,686 +$69,112,925 $27.36 149
2018 Q1 26,265,389 $553,921,588 +$48,054,177 $21.09 125
2017 Q4 24,161,330 $464,380,689 +$125,663,405 $19.22 104
2017 Q3 17,658,852 $438,844,579 +$20,568,797 $24.85 83
2017 Q2 16,794,955 $268,727,920 +$2,720,387 $16.00 80
2017 Q1 16,527,271 $232,868,748 -$10,218,348 $14.09 73
2016 Q4 18,132,413 $237,715,660 -$5,662,451 $13.11 64
2016 Q3 14,253,796 $242,822,100 +$997,930 $17.02 64
2016 Q2 14,055,535 $299,661,145 +$297,985,339 $21.35 61
2016 Q1 215 $4,000 $0 $18.60 1